ublituximab

10/16/2023 - "Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis."
07/01/2023 - "Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis."
01/01/2023 - "Ublituximab (Briumvi) for relapsing multiple sclerosis."
12/01/2022 - "Ublituximab: a new anti-CD20 agent for multiple sclerosis."
09/01/2022 - "Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS). "

04/01/2018 - "Ublituximab for the treatment of CD20 positive B-cell malignancies."
05/01/2013 - "Four to 7 days later, ublituximab was injected intracerebrally or intravitreously into the tumor site. "
02/01/2019 - "We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies. "
01/01/2020 - "Of the 79 antibodies, 39 were undergoing evaluation in late-stage studies for non-cancer indications, with 2 of these (ublituximab, pamrevlumab) also in late-stage studies for cancer indications. "
02/01/2018 - "Of the 12 candidates, 8 are for non-cancer indications (lanadelumab, crizanlizumab, ravulizumab, eptinezumab, risankizumab, satralizumab, brolucizumab, PRO140) and 4 are for cancer (sacituzumab govitecan, moxetumomab pasudotox, cemiplimab, ublituximab). "

01/01/2021 - "Ublituximab was assessed in relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorder, with promising results, however, the included number of patients was too small to conclude. "
10/01/2023 - "Briumvi, the fourth type of anti-CD20 antibody was approved by FDA in December 2022, for the treatment of relapsing types of MS, including relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis, and clinically isolated syndromes after the drug was tested in two randomized, double-blind, phase III, ULTIMATE I, and II trials which compared Briumvi (ublituximab) with Aubiago (teriflunomide). "

06/01/2019 - "To test the safety of ublituximab, a B cell depleting agent, as add-on therapy in the acute treatment of relapses of neuromyelitis optica spectrum disorder. "
01/01/2021 - "Ublituximab was assessed in relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorder, with promising results, however, the included number of patients was too small to conclude. "
06/01/2019 - "A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder."

01/01/2017 - "At the 2017 ASCO Meeting, results of the GENUINE phase III trial showed that, by adding ublituximab, a glycoengineered, anti-CD20 type 1 monoclonal antibody, to ibrutinib, the overall response rate (ORR), complete response rate (CRR), and minimal residual disease (MRD) negativity may be improved in high-risk CLL patients. "